EFM
SRPT icon

E Fund Management’s Sarepta Therapeutics SRPT Stock Holding History

E Fund Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$313K Sell
17,435
-3,018
-15% -$57.1K 0.01% 372
2026
Q1 		$445K Buy
+20,453
New +$396K 0.01% 306
2025
Q2 		$283K Buy
16,525
+7,416
+81% +$316K 0.01% 318
2025
Q1 		$581K Buy
9,109
+1,500
+20% +$158K 0.03% 209
2024
Q4 		$925K Sell
7,609
-1,107
-13% -$136K 0.05% 155
2024
Q3 		$1.09M Sell
8,716
-45
-0.5% -$6.22K 0.06% 136
2024
Q2 		$1.38M Buy
8,761
+5,276
+151% +$678K 0.08% 102
2024
Q1 		$451K Sell
3,485
-2,034
-37% -$249K 0.03% 172
2023
Q4 		$532K Buy
5,519
+1,705
+45% +$164K 0.03% 152
2023
Q3 		$462K Buy
3,814
+315
+9% +$35.6K 0.04% 133
2023
Q2 		$401K Buy
3,499
+815
+30% +$105K 0.03% 167
2023
Q1 		$370K Sell
2,684
-889
-25% -$115K 0.03% 194
2022
Q4 		$463K Sell
3,573
-449
-11% -$52K 0.04% 143
2022
Q3 		$445K Sell
4,022
-2,311
-36% -$233K 0.04% 150
2022
Q2 		$475K Buy
6,333
+2,887
+84% +$212K 0.04% 152
2022
Q1 		$269K Buy
+3,446
New +$264K 0.01% 237

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

E Fund Management's SRPT Position: Q2 2026 in Review

E Fund Management reduced its Sarepta Therapeutics (SRPT) stake by 15% in Q2 2026, selling an estimated $57.1K and leaving 17,435 shares worth $313K. The position accounts for 0.01% of the portfolio, ranked #372.

E Fund Management first reported a position in SRPT in Q1 2022 and has held it in 16 quarters since. The position peaked at $1.38M in Q2 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • E Fund Management held 17,435 shares of Sarepta Therapeutics worth $313K as of Q2 2026.
  • E Fund Management sold 3,018 Sarepta Therapeutics shares in Q2 2026, an estimated $57.1K.
  • Sarepta Therapeutics made up 0.01% of E Fund Management's portfolio in Q2 2026, its #372 holding.
  • E Fund Management first reported a position in Sarepta Therapeutics in Q1 2022 and has held it in 16 quarters since.
  • E Fund Management's Sarepta Therapeutics position peaked at $1.38M in Q2 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.